Infiltration of a mesothelioma by IFN-γ-producing cells and tumor rejection after depletion of regulatory T cells

Journal of Immunology

Volumn 178, Issue 7, 2007, Pages 4089-4096

  Rudge, Geordie ^a   Barrett, Simon P ^a   Scott, Bernadette ^b   Van Driel, Ian R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GK1.5 ANTIBODY; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR ANTIBODY; PC61 ANTIBODY; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; YTS169.4 ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; IMMUNOMODULATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MESOTHELIOMA; MITOSIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SOLID TUMOR; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNOLOGY; TUMOR REJECTION;

EID: 33947704281     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.7.4089     Document Type: Article

References (40)

1. + regulatory T cells that express Toll-like receptors. J. Exp. Med. 197: 397-401.
2. Shevach, E. M. 2000. Suppressor T cells: rebirth, function and homeostasis. Curr. Biol. 10: R572-R575.
3. von Boehmer, H. 2005. Mechanisms of suppression by suppressor T cells. Nat. Immunol. 6: 338-344.
4. reg cell-mediated suppression. J. Exp. Med. 203: 489-492.
5. Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6: 295-307.
6. + T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176: 1582-1587.
7. Marzo, A. L., R. A. Lake, D. Lo, L. Sherman, A. McWilliam, D. Nelson, B. W. Robinson, and B. Scott. 1999. Tumor antigens are constitutively presented in the draining lymph nodes. J. Immunol. 162: 5838-5845.
8. Marzo, A. L., R. A. Lake, B. W. Robinson, and B. Scott. 1999. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res. 59: 1071-1079.
9. + T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J. Immunol. 165: 6047-6055.
10. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22: 329-360.
11. Khong, H. T., and N. P. Restifo. 2002. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3: 999-1005.
12. Yamaguchi, T., and S. Sakaguchi. 2005. Regulatory T cells in immune surveillance and treatment of cancer. Semin. Cancer Biol. 2: 115-123.
13. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59: 3128-3133.
14. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163: 5211-5218.
15. Turk, M. J., J. A. Guevara-Patino, G. A. Rizzuto, M. E. Engelhorn, and A. N. Houghton, 2004. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200: 771-782.
16. Chen, M. L., M. J. Pittet, L. Gorelik, R. A. Flavell, R. Weissleder, H. von Boehmer, and K. Khazaie. 2005. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc. Natl. Acad. Sci. USA 102: 419-424.
17. + regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 32: 3267-3275.
18. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201: 779-791.
19. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174: 2591-2601.
20. + regulatory T cells. J. Exp. Med. 202: 885-891.
21. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
22. high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173; 1444-1453.
23. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61: 4766-4772.
24. Yu, P., and Y. X. Fu. 2006. Tumor-infiltrating T lymphocytes: friends or foes? Lab. Invest. 86: 231-245.
25. + T cell-mediated spontaneous diabetes in neonatal mice. J. Immunol. 157: 978-983.
26. + regulatory T cells inhibit the antigen-dependent expansion of self-reactive T cells in vivo. J. Immunol. 176: 1609-1617.
27. Lyons, A. B., and C. R. Parish. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171: 131-137.
28. Openshaw, P., E. E. Murphy, N. A. Hosken, V. Maino, K. Davis, K. Murphy, and A. O'Garra. 1995. Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations. J. Exp. Med. 182: 1357-1367.
29. Davis, M. R., L. S. Manning, D. Whitaker, M. J. Garlepp, and B. W. Robinson. 1992. Establishment of a murine model of malignant mesothelioma. Int. J. Cancer 52: 881-886.
30. + T regulatory cells. J. Immunol. 176: 3301-3305.
31. Wu, J., and L. L. Lanier. 2003. Natural killer cells and cancer. Adv. Cancer Res. 90: 127-156.
32. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. USA 96: 8633-8638.
33. Pulaski, B. A., M. J. Smyth, and S. Ostrand-Rosenberg. 2002. Interferon-γ-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma. Cancer Res. 62: 4406-4412.
34. + T cells requires tumor responsiveness to IFN-γ. J. Immunol. 166: 2276-2282.
35. Dighe, A. S., E. Richards, L. J. Old, and R. D. Schreiber. 1994. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors. Immunity 1: 447-456.
36. Kaplan, D. H., V. Shankaran, A. S. Dighe, E. Stockert, M. Aguet, L. J. Old, and R. D. Schreiber. 1998. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95: 7556-7561.
37. + cells controlling a pathogenic CD4 response inhibit cytokine differentiation, CXCR-3 expression, and tissue invasion. J. Immunol. 173: 2942-2951.
38. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188: 287-296.
39. + regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J. Immunol. 174: 1783-1786.
40. + regulatory T cells. J. Exp. Med. 202: 885-891.